Portola Pharmaceuticals Inc. (NASDAQ: PTLA) shares more than doubled on Tuesday after the company announced that it would be acquired by Alexion Pharmaceuticals Inc. (NASDAQ: ALXN).
According to the deal, Alexion will pay $18 per Portola share in cash, a premium of 132% to Portola’s last closing price, for an aggregate price of $1.41 billion.
Essentially, Alexion is paying for Portola’s treatment for reversing the effects of blood thinners. The treatment, Andexxa, was approved in the United States in 2018 and had sales of $111.5 million in 2019.
Alexion has been trying to maintain its position as the top dog in the treatment of certain rare blood disorders through a string of acquisitions to increase its pipeline of rare disease drugs.
Last year, Alexion agreed to buy Achillion Pharmaceuticals for $930 million to acquire its rare blood disorder experimental treatments.
Portola stock traded up about 130% on Tuesday to $17.80, in a 52-week range of $5.31 to $36.49. The consensus price target is $19.57.
Alexion stock was down about 4% to $99.30. The 52-week range is $72.67 to $136.51, and the consensus price target is $139.45.
Sponsored: Attention Savvy Investors: Speak to 3 Financial Experts – FREE
Ever wanted an extra set of eyes on an investment you’re considering? Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help guide you through the financial decisions you’re making. And the best part? The first conversation with them is free.Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.